DNA Stock Recent News

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks announced a series of new initiatives to accelerate the application of artificial intelligence in biologics drug discovery.

McDonald's CEO Chris Kempczinski joins 'Squawk Box' to discuss the launch of the new extra value menu, health of the consumer, cost pressures facing franchisees, the tax on tip debate, growth outlook, exiting the Russian market, importance of China, and more.

SECAUCUS, N.J. , Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.

BOSTON , Aug. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to deliver capabilities that previously required massive platform investments by combining high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service that could help scientists design better drugs with fewer resources.

After reaching an important support level, Ginkgo Bioworks Holdings, Inc. (DNA) could be a good stock pick from a technical perspective. DNA surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON , Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation.

Ginkgo Bioworks' shares have rallied tremendously, and Q2 results showed a headline revenue beat with no upward guidance revision. Biosecurity segment guidance was cut, and overall revenue estimates have plunged, raising concerns about future growth. Despite cost reductions, Ginkgo continues to post large operating losses and faces ongoing cash burn, prompting a $500 million shelf offering.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET Company Participants Daniel Waid Marshall - Senior Manager of Communications and Ownership Jason Kelly - Founder, CEO & Director Steven P. Coen - Chief Accounting Officer & CFO Daniel Waid Marshall Good evening.

Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON , Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON , July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.